ClinPGx Blog (Page 7)

Sign in Subscribe

More issues

PharmGKB Acyclovir/Ganciclovir Pathway Published

The PharmGKB Acyclovir/Ganciclovir Pathway has recently been published in the journal Pharmacogenetics and Genomics. Acyclovir (ACV) and ganciclovir (GCV) are commonly prescribed antivirals to treat infections caused by herpes viruses, varicella-zoster virus or cytomegalovirus (eg. cold sores, shingles and chicken pox, etc.). The pathway, co-developed by Maud Maillard along

Expansion of pharmacogenetics education agreed as part of lawsuit settlement

Oregon Health & Science University (OHSU) will introduce new educational initiatives on the risks of prescribing the chemotherapy drug capecitabine to patients with DPD deficiency as part of a lawsuit settlement. The settlement was reached with Joanne McIntyre, whose husband David died as a result of severe capecitabine toxicity. David

Update to PharmGKB Pediatric Summaries - BPCA Drugs

The latest round of PharmGKB’s pediatric drug summaries is now live on PharmGKB pediatric. This release includes summaries for 55 drugs, bringing the total summary count to over 180, now including all drugs on the Best Pharmaceuticals for Children Act (BPCA) priority list in addition to all CPIC guideline

Response to the American Academy of Pediatrics' Statement "Eliminating Race-Based Medicine"

On May 2nd, the American Academy of Pediatrics (AAP) released a pre-published policy statement titled “Eliminating Race-Based Medicine,” noting that race is a “historically derived social construct that has no place as a biologic proxy.” The statement provides necessary and meaningful commentary on “the medical field’s history of inaccurate

Ask a Curator for Healthcare Professionals on June 7th

We are holding an Ask a Curator zoom targeted towards healthcare professionals wanting to learn more about PharmGKB and pharmacogenomics. This is part of NHGRI’s Healthcare Professionals Genomics Education Week (#MedGeneEd22). Be sure to spread the word to colleagues who may find this useful. We are asking people to

What does *1 really mean? And why does that matter?

A Haiku about PGx for National Poetry Month. Diagnosed star one, Yet severe toxicity. What did the lab test? What does *1 really mean? And why does that matter? The star alleles of the drug metabolizing enzyme genes are an unusual way of defining variation and are perhaps one of

Update to PharmGKB Pediatric Drug Summaries

The third round of PharmGKB's pediatric drug summaries is now live on PharmGKB pediatric. This release includes over 20 additional drugs with a focus on those on the Best Pharmaceuticals for Children Act (BPCA) priority list, including: * Albendazole * Amphotericin b * Artesunate * Atropine * Baclofen * Benznidazole * Betamethasone * Canakinumab * Cefepime * Ceftazidime

"Ask a Curator" live zoom event

PharmGKB curators will hold a series of live Q&A events over Zoom to help people find and use different aspects of the knowledgebase. We hope this will be a great way to answer questions about PharmGKB and PGx which are specific to users’ individual needs or projects. These

National Academy Seeking Public Feedback on Use of Population Descriptors in Genomics Research

The National Academy's Committee on Use of Race, Ethnicity, and Ancestry as Population Descriptors in Genomics Research is now actively requesting public comments from those involved in genomics research about how they use descriptors like race, ethnicity, and ancestry as well as thoughts on potential improvements to usage.

Retirement of CYP3A5 alleles in PharmVar

The PharmVar CYP3A5 expert panel has undertaken an extensive review of CYP3A5 allelic variation which led to the retirement of three star alleles, namely CYP3A5*2, *4 and *5. Based on new data, their defining variants were always found together with the CYP3A5*3-defining splice defect (c.219-237) meaning that